1. Therapeutic Agents in Phase III Clinical Trials for Alzheimer’s (Registration Trials)
Aducanumab: amyloid antibody
Biogen
Albumin + Immunoglobulin: treats primary immunodeficiency
Grifols Biologicals
ALZT-OP1: Mast cell stabilizer + anti- inflammatory
AZTherapies
CAD-106: amyloid vaccine
Novartis
CNP520: BACE inhibitor
Crenezumab: amyloid antibody
Hoffmann-La Roche
Elenbecestat (E2609): BACE inhibitor
Eisai, Biogen
Gantenerumab: amyloid antibody
Levetiracetam: beta-amyloid production inhibitor
AgeneBio
MB2 (TRx0237, Methylene Blue): tau aggregation inhibitor
TauRx Therapeutics Ltd
Sodium oligo-mannurarate (GV-971): inhibits beta-amyloid aggregation
Shanghai Greenvalley Pharmaceuticals
Solanezumab: amyloid antibody
Eli Lilly
Trigriluzole: Pro-drug of riluzole, a glutamate modulator agent 
Biohaven Pharmaceuticals
For related symptoms:
AVP-786 (agitation): combination of Deuterated [d6]-Dextromethorphan Hydrobromide and Quinidine Sulfate
Avanir Pharmaceuticals
AXS-05 (agitation): combination of bupropion (NDRI) and dextromethorphan (NMDA receptor antagonist)
Axsome Therapeutics
Brexpiprazole (agitation): dopamine D2 receptor partial agonist
Otsuka Pharmaceuticals
ITI-007 (agitation): 5-HT2A receptor antagonist
Intra-Cellular Therapies
Pimavanserin (psychosis): selective inverse agonist of serotonin 5-HT2A receptor
Acadia Pharmaceuticals
Suvorexant (Belsomra®) (sleep): orexin receptor antagonist
Merck Sharp & Dohme
As of 10/2018

2. Therapeutic Agents in Phase III Clinical Trials for Alzheimer’s (Academic Trials)
Candesartan: Angiotensin receptor blocker
Ihab M. Hajjar, Emory University
Curcumin: nutritional supplement
University of Florida
Ergothioneine: nutritional supplement
National University Hospital, Singapore
Gantenerumab: amyloid antibody
Washington University School of Medicine, Hoffmann-La Roche
Ginkgo biloba (with or without donepezil): nutritional supplement
First Affiliated Hospital with Nanjing Medical University
Guanfacine: α2A receptor agonist
Imperial College London
Human neural stem cells: pluripotent cell line
Second Affiliated Hospital of Soochow University
Icosapent Ethyl/ Omega-3 fatty acid: nutritional
VA Office of Research and Development; University of Southern California
Insulin (intranasal): Hormone controlling blood sugar
University of Southern California
Lisinopril: Angiotensin receptor blocker
Ihab M. Hajjar, Emory University
Losartan, Amlodipine & Atorvastatin combination therapy: blood pressure reducers
University of Texas Southwestern Medical Center
Octohydroaminoacridine Succinate: acetylcholinesterase inhibitor
Shanghai Mental Health Center
Vitamin D3: nutritional supplement
University Hospital, Tours
For related symptoms:
Carbamazepine (agitation): voltage-gated sodium channel blocker
University of Sussex
Escitalopram (agitation): selective serotonin reuptake inhibitor (SSRI)
Johns Hopkins School of Public Health Center for Clinical Trials
Escitalopram (alone or with Memantine): selective serotonin reuptake inhibitor (SSRI) (Depression)
University of California, Los Angeles
Methylphenidate: norepinephrine–dopamine reuptake inhibitor (NDRI) (Apathy)
Johns Hopkins Bloomberg School of Public Health
Mirtazapine (agitation): atypical antidepressant
University of Sussex
Nabilone/ Dronabinol (agitation): synthetic cannabinoid
Sunnybrook Health Sciences Centre
Zolpidem (sleep): Short-acting nonbenzodiazepine
Brasilia University Hospital
Zoplicone (sleep): Nonhypnotic sleep aid
As of 10/2018